CK20 Positive: What It Means for Your Health

A CK20-positive result on a pathology report means that cells in a tissue sample are producing cytokeratin 20, a structural protein normally found in the lining of the intestines, the bladder’s inner surface, and specialized skin cells called Merkel cells. On its own, a CK20-positive finding is not a diagnosis. It is one piece of a puzzle that pathologists use, usually alongside other markers, to figure out what type of cell they are looking at and, in cancer cases, where a tumor likely started.

What CK20 Actually Is

CK20 belongs to a family of proteins called cytokeratins, which form a kind of internal scaffolding inside epithelial cells. Think of these proteins as the support beams that help cells keep their shape and hold together as a tissue. CK20 plays a role in maintaining this scaffolding specifically in intestinal cells, where research in animal models has shown it works alongside another cytokeratin, CK18, to keep the filament network properly organized.¹

In a healthy body, CK20 shows up in a very limited set of tissues. You will find it in the cells lining the stomach, small intestine, and colon; in the umbrella cells that line the bladder; and in Merkel cells, the touch-sensitive cells deep in the skin. Because CK20 is restricted to these locations rather than being scattered throughout the body, its presence in a tissue sample tells a pathologist something useful: the cells likely originated from one of those specific places.

Why Pathologists Care About CK20

When a pathologist examines a tumor under the microscope, the cells do not always look distinctive enough to reveal where they came from. This is especially true when cancer has spread. A tumor found in the liver, for example, could be a primary liver cancer or a metastasis from the colon, pancreas, stomach, or elsewhere. CK20 staining helps narrow that list down.

Pathologists rarely use CK20 alone. They almost always pair it with CK7, another cytokeratin that has a different distribution in the body. CK7 tends to show up in the lungs, breast, ovaries, and upper gastrointestinal tract. By combining the two results, pathologists get four possible profiles, each pointing toward different organs of origin.²

CK20 positive, CK7 negative: Strongly suggests a colorectal origin. This is the classic pattern for colon and rectal cancers.
CK20 positive, CK7 positive: Points toward the bladder (urothelial carcinoma), mucinous ovarian tumors, or cancers of the pancreas and bile ducts.
CK20 negative, CK7 positive: Common in lung, breast, and endometrial cancers.
CK20 negative, CK7 negative: Seen in some liver, kidney, and prostate cancers.

These profiles are guidelines, not guarantees. A recent review of how pathologists actually use CK7 and CK20 staining found that when both stains are ordered together, their results make a major contribution to the diagnosis in only a small fraction of cases where the question is specifically about where the tumor started. In many cases, the staining pattern turns out to be inconsistent with the final diagnosis reached through other evidence.³ That does not mean the stains are useless, but it does mean your pathologist is considering many other factors alongside them.

CK20 Positive and Colorectal Cancer

The strongest and most well-known association with CK20 positivity is colorectal cancer. Most colon and rectal tumors light up for CK20 and stay negative for CK7. One study found this CK7-negative/CK20-positive pattern in about 64% of colorectal cancers, with a specificity above 96% for predicting a colorectal origin. That same pattern appeared in only 5% of stomach cancers and none of the pancreatic cancers examined.⁴

However, not all colorectal cancers follow this expected pattern. A study of colorectal carcinomas identified four distinct CK20/CK7 profiles: about 60% were CK20-positive/CK7-negative (the classic pattern), roughly 35% were negative for both markers, and small minorities showed the other combinations.⁵ The fact that over a third of colorectal cancers may not show the “typical” CK20-positive pattern is something pathologists keep in mind. A CK20-negative result does not rule out colorectal cancer.

CK20 in Merkel Cell Carcinoma

Merkel cell carcinoma is a rare but aggressive skin cancer, and CK20 plays a central role in its diagnosis. Under the microscope, Merkel cell carcinoma can look very similar to other small round cell tumors, including small cell lung cancer and lymphoma. CK20 staining helps pathologists distinguish it because Merkel cell carcinoma produces CK20 in a distinctive “perinuclear dot-like” pattern, where the stain concentrates in a single bright spot near the center of each cell rather than spreading throughout it.⁶

This dot pattern is highly characteristic. Research comparing Merkel cell carcinoma with other neuroendocrine cancers found that the dot-like staining for neurofilament, another marker commonly used alongside CK20, appeared in about 75% of Merkel cell carcinoma cases but was exceedingly rare in neuroendocrine tumors from other organs.⁷ If your pathology report mentions CK20-positive staining with a dot-like pattern in a skin lesion, your doctor is very likely considering Merkel cell carcinoma.

CK20 and Bladder Cancer

In the normal bladder, CK20 production is limited to the umbrella cells, the outermost layer of the lining. When bladder cells become abnormal or cancerous, CK20 often gets turned on more broadly, which is one reason pathologists use it when evaluating bladder biopsies for early-stage disease and carcinoma in situ.⁸

In bladder cancer, CK20 positivity is a feature of what researchers call the “luminal” molecular subtype. A large study of over 2,700 bladder cancers found CK20 staining in roughly half of all cases. Interestingly, the proportion of strongly CK20-positive tumors increased from early-stage to intermediate-stage disease but then dropped in the most advanced, muscle-invasive cancers.⁸ This pattern suggests that as bladder tumors become more aggressive and dedifferentiated, they may stop producing CK20.

For diagnosis, CK20 positivity in a bladder tumor combined with CK7 positivity helps distinguish it from a colorectal metastasis to the bladder, since colorectal cancers are typically CK7 negative.⁹ This distinction matters because a colorectal cancer that has spread to the bladder requires completely different treatment than a primary bladder cancer.

Tracing an Unknown Primary Tumor

One of the most practically important uses of CK20 is in the workup for cancers of unknown primary, where a metastatic tumor is found but no one yet knows where it started. This is not an unusual scenario; it accounts for a meaningful percentage of new cancer diagnoses. CK20 and CK7 staining, along with other tissue-specific markers, form the backbone of the immunohistochemical approach pathologists use to track down the origin.¹⁰

When a metastasis turns up in the liver, the CK20/CK7 combination can be especially telling. Research on liver metastases found that tumors with a CK20-positive/CK7-negative profile were colorectal in origin about 80% of the time, while tumors that were positive for both CK20 and CK7 came from the pancreas or bile ducts in a similarly high percentage of cases.¹¹ For patients and their oncologists, pinpointing the origin shapes everything from the choice of chemotherapy to the value of further imaging and screening.

CK20 results also help with mucinous ovarian tumors. The question that often arises is whether a mucinous tumor in the ovary started there or spread from the gastrointestinal tract. Primary ovarian mucinous tumors express both CK7 and CK20 in about two-thirds of cases, but they are CK7-negative/CK20-positive in only about 7% of the time. A metastasis from the colon, by contrast, would typically show that CK7-negative/CK20-positive pattern.¹² Pathologists weigh this alongside clinical history and other markers to reach the right call, which directly affects surgical and chemotherapy decisions.

Does CK20 Status Affect Prognosis

CK20 is primarily a diagnostic tool rather than a prognostic one, but in certain settings its presence or absence carries prognostic weight. In colorectal cancer, the loss of CK20 expression can actually signal a worse outlook. Tumors that have lost both CK20 and CDX2 (another intestinal marker) tend to be more poorly differentiated and are associated with higher stage, more frequent lymph node spread, and worse overall and disease-free survival.¹³ Separately, loss of CK20 in colorectal cancer has been linked to higher tumor grade and the presence of tumor-infiltrating immune cells.¹⁴

The paradox here is worth noting. In diagnostics, CK20 positivity helps confirm a colorectal origin. But within colorectal cancer specifically, the tumors that have lost CK20 are often the most dangerous. This can occasionally cause confusion on pathology reports. A poorly differentiated colorectal cancer that has lost CK20 may not “look” like a colorectal cancer on staining, making it harder to identify if it shows up as a metastasis somewhere else.

In bladder cancer, the relationship between CK20 and outcomes is less clear-cut. While CK20 is used diagnostically to identify carcinoma in situ, research on bladder carcinoma in situ found that patients with CK20-negative cases had clinical outcomes similar to those with CK20-positive cases, meaning a negative CK20 result should not reassure a patient that the disease is less serious.¹⁵

CK20 in Blood Tests for Circulating Tumor Cells

Beyond its role in tissue biopsies, CK20 has found a second life in liquid biopsy research. Because CK20 is so specific to intestinal-type cells, detecting its genetic material in a blood sample can indicate that colorectal cancer cells are circulating in the bloodstream. These circulating tumor cells are a sign that the cancer has the ability to travel, which carries implications for recurrence and survival.

A prospective study of colon cancer patients found that those with CK20-detectable circulating tumor cells in their blood had a five-year overall survival rate of 68%, compared with 85% in patients without detectable cells. In a statistical analysis accounting for other risk factors, the presence of CK20-positive circulating tumor cells was independently associated with roughly double the risk of death or disease recurrence.¹⁶ Other research has confirmed that adding CK20 as a biomarker improves the detection of circulating tumor cells in metastatic colorectal cancer patients.¹⁷

This type of testing is not yet part of routine clinical care for most patients, but it represents a growing area of interest. The idea is that monitoring CK20 levels in the blood could eventually help oncologists detect recurrences earlier or gauge how well a treatment is working, without needing repeated tissue biopsies.

CK20 in Non-Cancer Conditions

Not every CK20-positive result means cancer. The protein plays a role in diagnosing Barrett’s esophagus, a condition where the lining of the lower esophagus changes to resemble intestinal tissue, typically due to chronic acid reflux. Distinguishing Barrett’s esophagus from a similar-looking change called intestinal metaplasia of the stomach matters because Barrett’s carries a higher risk of progressing to esophageal cancer and requires different surveillance.

Researchers identified a distinctive CK7/CK20 staining pattern in Barrett’s esophagus: CK20 staining concentrated in the surface layer, with strong CK7 staining throughout both the surface and deeper glands. This pattern was present in 94% of esophageal tissue samples from Barrett’s patients and in 100% of biopsy specimens, but was absent in all gastric samples with intestinal metaplasia.¹⁸ Subsequent work has explored whether this pattern holds up in shorter segments of Barrett’s esophagus with more variable results, suggesting it works best for longer-segment disease.¹⁹

Reading Your Pathology Report

If you are looking at a pathology report that mentions CK20, the most important thing to understand is that it is one data point among many. Pathologists interpret CK20 results in the context of the full panel of stains ordered, the appearance of the cells under the microscope, imaging findings, and clinical history. A CK20-positive result in a known colon biopsy is expected and unremarkable. A CK20-positive result in a tumor found in the liver or lung is more informative because it narrows the list of possible origins.

It also helps to know that no immunohistochemical stain is perfect. Tumors can gain or lose markers as they grow and spread. A large tissue microarray study examining over 15,000 cancers confirmed that the combined CK7/CK20 profile has its best diagnostic value in CK20-positive tumors specifically, where CK7 negativity typically points to a colorectal source and CK7 positivity argues for bladder or mucinous ovarian cancer.⁹ But exceptions exist in every cancer type, and experienced pathologists account for these by using additional markers and clinical context rather than relying on CK20 alone.

When discussing results with your doctor, the questions worth asking are less about the CK20 result itself and more about what the full staining panel and the overall clinical picture suggest. CK20 is the pathologist’s compass needle, helpful for pointing toward a direction, but the destination requires more than a single reading to confirm.